Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses

Bibliographic Details
Main Authors:	Qian He, Shuying Liu, Zhenglun Liang, Shan Lu, Wei Cun, Qunying Mao
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Emerging Microbes and Infections
Subjects:	SARS-CoV-2 DNA vaccine protein vaccine heterologous prime – boost antibody T cells
Online Access:	https://www.tandfonline.com/doi/10.1080/22221751.2022.2152388

Similar Items

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
by: Jialu Zhang, et al.
Published: (2021-01-01)

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
by: Shixia Wang, et al.
Published: (2017-12-01)

DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses
by: Haiying Li, et al.
Published: (2021-01-01)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
by: Jialu Zhang, et al.
Published: (2022-12-01)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
by: Qian He, et al.
Published: (2021-01-01)

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity
by: Fernanda Caroline Coirada, et al.
Published: (2023-06-01)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
by: Zhuxiang Zhao, et al.
Published: (2022-12-01)

The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule
by: Gretel Naidich, et al.
Published: (2023-04-01)

Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming
by: Laura E. Johnson, et al.
Published: (2018-08-01)

Vaccination strategies, the power of the unmatched double hits
by: Talal S Al-Qaisi, et al.
Published: (2023-10-01)

The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine
by: Surakameth Mahasirimongkol, et al.
Published: (2022-03-01)

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
by: Gabiria Pastore, et al.
Published: (2024-12-01)

The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China
by: Hudachuan Jiang, et al.
Published: (2023-12-01)

Heterologous Prime-Boost Immunization with DNA Vaccine and Modified Recombinant Proteins Enhances Immune Response against <i>Trueperella pyogenes</i> in Mice
by: Ting Huang, et al.
Published: (2022-05-01)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
by: Noopur Bhatnagar, et al.
Published: (2023-07-01)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
by: Chong Li, et al.
Published: (2020-07-01)

Alternating 3 different influenza vaccines for swine in Europe for a broader antibody response and protection
by: Anna Parys, et al.
Published: (2022-06-01)

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
by: Lynette Siv Chea, et al.
Published: (2017-10-01)

Orf virus DNA prime-protein boost strategy is superior to adenovirus-based vaccination in mice and sheep
by: Yan Wang, et al.
Published: (2023-03-01)

Heterologous prime-boost H1N1 vaccination exacerbates disease following challenge with a mismatched H1N2 influenza virus in the swine model
by: Vasilis C. Pliasas, et al.
Published: (2023-10-01)

Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice
by: Juan Wu, et al.
Published: (2022-10-01)

Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review
by: Ishan Garg, et al.
Published: (2022-07-01)

A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
by: Farokh Dotiwala, et al.
Published: (2022-09-01)

Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea
by: Yunhyung Kwon, et al.
Published: (2022-12-01)

Efficacy of Heterologous Prime-Boost Vaccination with H3N2 Influenza Viruses in Pre-Immune Individuals: Studies in the Pig Model
by: Sharon Chepkwony, et al.
Published: (2020-09-01)

Prime-Boost Vaccine Regimen for SjTPI and SjC23 Schistosome Vaccines, Increases Efficacy in Water Buffalo in a Field Trial in China
by: Akram A. Da'Dara, et al.
Published: (2019-02-01)

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial
by: Leyla Sharifi Aliabadi, et al.
Published: (2023-08-01)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac–ChAdOx1
by: Saipin Pongsatha, et al.
Published: (2023-01-01)

Heterologous Systemic Prime–Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as well as Protection in Hamsters
by: Paidamoyo M. Katsande, et al.
Published: (2022-11-01)

DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis
by: Karine M Forster, et al.
Published: (2015-12-01)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
by: Szu-Ting Huang, et al.
Published: (2023-11-01)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
by: Jianyang Liu, et al.
Published: (2023-12-01)

Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2
by: Brigitte Müller-Hilke, et al.
Published: (2022-02-01)

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2023-05-01)

Corrigendum: Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2024-02-01)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
by: Jaejo Kim, et al.
Published: (2023-02-01)

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy
by: Zsolt Matula, et al.
Published: (2022-03-01)

T-cell-mediated cross-strain protective immunity elicited by prime–boost vaccination with a live attenuated influenza vaccine
by: Junwei Li, et al.
Published: (2014-10-01)

Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial
by: Saeed Erfanpoor, et al.
Published: (2024-02-01)

An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine
by: Hana M El Sahly, et al.
Published: (2020-12-01)